Sign in
Active, not recruitingPhase 4

Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders

Key facts

Who runs it
Research Center of Neurology, Russia
Where
Russia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
30 people enrolled
Started
1 Apr 2026
Expected to end
25 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Mexidol sequential therapy
Record updated
6 November 2026

Who can take part

Age
50 years to 74 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • cerebrovascular disease (I67.8) and/or cerebral atherosclerosis (I67.2)
  • metabolic disorders (diabetes and/or BMI 27 or higher) for Group1
  • no metabolic disorders - for Group 2

Who cannot take part

  • history of neoplasia
  • acute stroke/myocardial infarction
  • decompensated somatic pathology

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

We aim to elucidate the metabolic and neuroactive properties of sequential Mexidol therapy in patients with and without cerebrometabolic disorders using blood biomarkers, anthropometry and brain functional MRI (task- and rest).

The 2 groups in the trial

  • Cerebrovascular disease without metabolic disordersExisting treatment, for comparison

    Treatment: Mexidol sequential therapy

  • Cerebrovascular disease with metabolic disorders (obesity and/or DM2)Treatment being tested

    Treatment: Mexidol sequential therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
6 November 2026